Reversal of Ventricular Remodeling With Toprol-XL

AstraZeneca

Status and phase: Completed; Phase 3

Conditions: Heart Failure, Congestive

Treatments: Drug: Seloken ZOK/Toprol-XL; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00038077

276

USMET0002

Details and patient eligibility

About

The purpose of this study is to determine whether treatment with Toprol-XL for 12 months in asymptomatic heart failure subjects will improve their heart structure and thus prevent the progression to symptomatic disease.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of stable asymptomatic heart failure.
• Documented ejection fraction less than 0.40.
• Must be able to comply with all study procedures.

Exclusion criteria

• Taken B-blocker therapy for longer than 1 week within 6 months prior to randomization.
• Have heart problems that would not allow B-blocker therapy.
• Receiving B-blockers therapy for any medical reason including topical B-blockers that might cause systemic absorption (e.g., glaucoma).
• Undergone certain heart surgeries, such as, prior heart transplant or cardiomyoplasty.
• Have certain heart diseases.
• Pregnant or breast feeding.
• Unlikely to survive.